Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for ENVB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
December 31, 2019 12.68%
September 30, 2019 14.62%
June 30, 2019 16.52%
March 31, 2019 14.78%
December 31, 2018 12.34%
September 30, 2018 16.16%
June 30, 2018 14.26%
March 31, 2018 13.76%
December 31, 2017 10.08%
September 30, 2017 13.94%
June 30, 2017 12.28%
March 31, 2017 21.17%
December 31, 2016 11.53%
September 30, 2016 11.80%
June 30, 2016 21.18%
March 31, 2016 43.29%
December 31, 2015 42.04%
September 30, 2015 32.05%
June 30, 2015 24.79%
March 31, 2015
December 31, 2014
September 30, 2014
June 30, 2014
March 31, 2014
December 31, 2013
Date Value
September 30, 2013
June 30, 2013
March 31, 2013
December 31, 2012
September 30, 2012
June 30, 2012
March 31, 2012
December 31, 2011
September 30, 2011
June 30, 2011
March 31, 2011
December 31, 2010
September 30, 2010
June 30, 2010
March 31, 2010
December 31, 2009
September 30, 2009
June 30, 2009
March 31, 2009
December 31, 2008
September 30, 2008
June 30, 2008
March 31, 2008
December 31, 2007
September 30, 2007 98.34%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
LENZ Therapeutics, Inc. 94.90%
Impact BioMedical, Inc. -9.40K%
ANI Pharmaceuticals, Inc. 54.97%
Corcept Therapeutics, Inc. 98.41%
Veru, Inc. --

Gross Profit Margin (Quarterly) Related Metrics